Mera Pharmaceuticals, Inc. (MRPI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mera Pharmaceuticals, Inc. (MRPI) trades at $0.0001. Mera Pharmaceuticals, Inc. focuses on developing and commercializing natural products from microalgae using proprietary photobioreactor technology. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for MRPI: MRPI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MRPI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MRPI: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Mera Pharmaceuticals, Inc. (MRPI) Healthcare & Pipeline Overview
Mera Pharmaceuticals, Inc., operating in the biotechnology sector, focuses on developing and commercializing natural products derived from microalgae using its proprietary photobioreactor technology, alongside ventures in sea salt, martial arts-based entertainment, and food services, distinguishing it within the healthcare landscape.
What Is the Investment Thesis for MRPI?
Mera Pharmaceuticals, Inc. presents a speculative investment opportunity due to its diverse business segments, including biotechnology, sea salt production, martial arts entertainment, and food services. The company's focus on natural products from microalgae offers potential in the growing market for sustainable and health-focused products. However, the company's negative P/E ratio of -10000.00 and high beta of 17.76 indicate significant financial risk and volatility. Successful commercialization of its microalgae-derived products and effective management of its diverse operations are critical for future growth. Investors should carefully consider the risks associated with OTC-listed companies and the company's limited financial information.
Based on FMP financials and quantitative analysis
MRPI Key Highlights
Mera Pharmaceuticals, Inc. operates in the biotechnology sector, focusing on natural products from microalgae.
- The company has a negative P/E ratio of -10000.00, indicating current unprofitability.
- The company's beta of 17.76 suggests high volatility compared to the market.
- Mera Pharmaceuticals, Inc. has diversified operations including sea salt production, a martial arts-based entertainment center, and food services.
- The company's market capitalization is $0.00B, reflecting its small size and potential risk.
Who Are MRPI's Competitors?
MRPI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MRPI's Key Strengths?
Proprietary photobioreactor technology.
- Diversified business operations.
- Focus on natural and health-focused products.
- Established presence in Las Vegas.
What Are MRPI's Weaknesses?
Negative P/E ratio indicating unprofitability.
- High beta suggesting high volatility.
- Limited financial information available.
- Small market capitalization.
What Could Drive MRPI Stock Higher?
Development and commercialization of new microalgae-derived products.
- Expansion of the family entertainment center to new locations.
- Potential strategic partnerships with healthcare companies.
- Introduction of new sea salt product variations.
- Enhancement of food production and delivery services.
What Are the Key Risks for MRPI?
Intense competition in the biotechnology and healthcare sectors.
- Evolving regulations in the food and drug industries.
- Economic downturn affecting consumer spending.
- Negative P/E ratio indicating unprofitability.
- High beta suggesting high volatility.
What Are the Growth Opportunities for MRPI?
- Expansion of Microalgae Product Line: Mera Pharmaceuticals can capitalize on the growing demand for natural and sustainable products by expanding its range of microalgae-derived products. This includes developing new applications in nutraceuticals, cosmetics, and pharmaceuticals. The global microalgae market is projected to reach $4.9 billion by 2027, offering significant growth potential. Successful product development and marketing could drive revenue growth within the next 3-5 years.
- Strategic Partnerships in Healthcare: Forming strategic alliances with established healthcare companies can provide Mera Pharmaceuticals with access to wider distribution networks, research expertise, and funding. Collaborations focused on developing microalgae-based therapies or diagnostic tools could accelerate product development and commercialization. These partnerships could materialize within the next 2-3 years, contingent on successful negotiations and clinical trial outcomes.
- Geographic Expansion of Entertainment Center: The company's family entertainment center focused on martial arts presents an opportunity for geographic expansion. Opening new locations in areas with a high interest in health and wellness activities could generate additional revenue streams. Each new center requires capital investment and market research, with a potential timeline of 1-2 years per location.
- Development of Sea Salt Products: Mera Pharmaceuticals can further develop its sea salt business by introducing new product variations, such as flavored salts or mineral-enriched salts. Expanding distribution channels through partnerships with retailers and online platforms can increase market reach. The global sea salt market is expected to grow, driven by increasing consumer awareness of the health benefits of natural salts. This expansion could be implemented within the next year.
- Enhancement of Food Production and Delivery Services: Improving the efficiency and quality of its food production and delivery services can attract more customers and increase market share. Implementing technology-driven solutions, such as online ordering platforms and optimized delivery routes, can enhance customer experience and reduce operational costs. This enhancement can be implemented within the next 6-12 months.
What Are MRPI's Competitive Advantages?
- Proprietary photobioreactor technology for microalgae cultivation.
- Diversified business operations across multiple sectors.
- Focus on natural and health-focused products and services.
- Established presence in the Las Vegas market.
What Does MRPI Do?
Founded in 1983 and based in Las Vegas, Nevada, Mera Pharmaceuticals, Inc. is a diversified company with a focus on the development and commercialization of natural products derived from microalgae. The company utilizes its proprietary and large-scale photobioreactor technology to cultivate microalgae and extract valuable compounds for various applications. Beyond its core biotechnology focus, Mera Pharmaceuticals is also involved in the production of sea salt. Additionally, the company operates a family entertainment center centered around the Villari's system of martial arts, promoting health and wellness. Mera Pharmaceuticals also provides food production and delivery services, further diversifying its business operations. The company's multifaceted approach aims to leverage natural resources and health-focused activities to create a sustainable business model.
What Products and Services Does MRPI Offer?
- Develops and commercializes natural products from microalgae.
- Utilizes proprietary photobioreactor technology for microalgae cultivation.
- Produces sea salt.
- Operates a family entertainment center focused on martial arts.
- Provides food production and delivery services.
- Focuses on health and wellness through its various business segments.
How Does MRPI Make Money?
- Generates revenue from the sale of microalgae-derived products.
- Earns income from sea salt production and distribution.
- Receives revenue from the operation of its family entertainment center.
- Derives income from food production and delivery services.
What Industry Does MRPI Operate In?
Mera Pharmaceuticals, Inc. operates within the biotechnology and healthcare sectors, which are characterized by rapid innovation, evolving regulations, and intense competition. The market for natural products derived from microalgae is growing, driven by increasing consumer demand for sustainable and health-focused ingredients. However, the company also competes in the sea salt, entertainment, and food service industries, each with its own set of market dynamics and competitive pressures. The biotechnology industry is expected to continue growing, driven by advancements in research and development and increasing healthcare spending.
Who Are MRPI's Key Customers?
- Consumers seeking natural and sustainable products.
- Individuals interested in health and wellness activities.
- Customers of the family entertainment center.
- Consumers of food production and delivery services.
Company Profile
Mera Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Edmundo Gonzalez. MRPI has traded publicly since 1995.
Key Financial Metrics
Return on equity for Mera Pharmaceuticals, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Mera Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
MRPI Financials
Bull Case vs Bear Case
Bull Case
- Proprietary photobioreactor technology.
- Diversified business operations.
- Focus on natural and health-focused products.
- Established presence in Las Vegas.
Bear Case
- Negative P/E ratio indicating unprofitability.
- High beta suggesting high volatility.
- Limited financial information available.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MRPI Latest News
No recent news available for MRPI.
MRPI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MRPI.
Price Targets
Wall Street price target analysis for MRPI.
MRPI MoonshotScore
What does this score mean?
The MoonshotScore rates MRPI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Benny Doro
CEO
Benny Doro serves as the CEO of Mera Pharmaceuticals, Inc. His professional background includes experience in business management and strategic development. He has been involved in overseeing the company's diverse operations, including biotechnology, sea salt production, entertainment, and food services. His leadership focuses on driving growth and innovation across the company's various business segments.
Track Record: Under Benny Doro's leadership, Mera Pharmaceuticals, Inc. has focused on expanding its product offerings and exploring new market opportunities. Key milestones include the development of its microalgae-derived products and the operation of its family entertainment center. However, the company's financial performance remains a challenge, as reflected in its negative P/E ratio.
MRPI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Mera Pharmaceuticals, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to listed companies.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight.
- Verify the company's business operations and revenue sources.
- Review the company's financial statements, if available.
- Assess the company's management team and their experience.
- Research the company's regulatory filings and compliance history.
- Evaluate the company's market position and competitive landscape.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investments.
- Operational business segments including biotechnology, sea salt, entertainment, and food services.
- Proprietary photobioreactor technology for microalgae cultivation.
- Established presence in the Las Vegas market.
- CEO leadership with experience in business management.
Common Questions About MRPI (Healthcare)
What does Mera Pharmaceuticals, Inc. do?
Mera Pharmaceuticals, Inc. is a diversified company operating in the healthcare and consumer sectors. Its primary focus is on developing and commercializing natural products derived from microalgae using its proprietary photobioreactor technology.
What are the potential applications of Mera Pharmaceuticals, Inc.'s microalgae technology in healthcare?
Mera Pharmaceuticals, Inc.'s microalgae technology holds promise for various applications in the healthcare sector. Microalgae can be a source of valuable compounds with potential therapeutic benefits, such as antioxidants, anti-inflammatory agents, and immune-boosting substances. The company could explore developing microalgae-based nutraceuticals, dietary supplements, or even pharmaceutical products targeting specific health conditions. Collaborations with research institutions and pharmaceutical companies could accelerate the development and commercialization of these healthcare applications.
What are the main risks for MRPI?
Mera Pharmaceuticals, Inc. faces several risks, including intense competition in the biotechnology and healthcare sectors, evolving regulations in the food and drug industries, and the potential for an economic downturn affecting consumer spending. The company's negative P/E ratio and high beta indicate financial challenges and volatility.
What are the key factors to evaluate for MRPI?
Evaluate MRPI on fundamentals, analyst consensus, and risk factors. Mera Pharmaceuticals, Inc. presents a speculative investment opportunity due to its diverse business segments, including biotechnology, sea salt production, martial arts entertainment, and food services. Not financial advice.
How frequently does MRPI data refresh on this page?
MRPI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MRPI's recent stock price performance?
Mera Pharmaceuticals, Inc. (MRPI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary photobioreactor technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MRPI overvalued or undervalued right now?
Mera Pharmaceuticals, Inc. (MRPI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MRPI before investing?
Before investing in Mera Pharmaceuticals, Inc. (MRPI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available for Mera Pharmaceuticals, Inc.
- OTC market investments carry higher risk.